Welcome to our dedicated page for Bio-Path Hldgs news (Ticker: BPTH), a resource for investors and traders seeking the latest updates and insights on Bio-Path Hldgs stock.
Bio-Path Holdings, Inc. (BPTH) generates frequent news as a clinical-stage biotechnology company developing RNAi nanoparticle drugs using its proprietary DNAbilize® liposomal antisense platform. Company announcements focus on progress across its oncology and obesity programs, including clinical trial updates, preclinical data, intellectual property developments, and corporate actions.
News coverage commonly highlights the Phase 2 trial of prexigebersen (BP1001) in acute myeloid leukemia and other blood cancers, where Bio-Path has reported extended treatment durability and complete remissions in elderly AML patients treated with combinations that include prexigebersen. Regular updates also cover the Phase 1/1b trial of BP1001-A in advanced solid tumors, including reports of tumor reduction and stable disease in heavily pretreated gynecologic cancer patients.
Another recurring theme in BPTH news is the exploration of BP1001-A as a potential treatment for obesity and related metabolic diseases in Type 2 diabetes patients. Press releases describe preclinical studies in muscle and liver cell models showing improved insulin sensitivity and restored insulin signaling, along with milestones in the path toward an Investigational New Drug (IND) application.
Investors following BPTH news will also see updates on BP1002 for relapsed or refractory AML, including venetoclax-resistant patients, and BP1003 targeting STAT3, as well as reports on patent issuances that expand the company’s DNAbilize® intellectual property portfolio. In addition, SEC filings and corporate press releases provide information on financing efforts, operational pauses, leadership changes, and the company’s transition from Nasdaq listing to trading on over-the-counter markets. This news page aggregates these developments so readers can track Bio-Path’s clinical, scientific, and corporate trajectory over time.
Bio-Path Holdings (NASDAQ:BPTH) has provided its 2025 clinical development and operational update, highlighting progress across multiple programs. The company is advancing its DNAbilize® platform in both oncology and a new application for obesity treatment in Type 2 Diabetes patients.
Key developments include: a Phase 2 clinical trial for prexigebersen in acute myeloid leukemia (AML) with three cohorts; an ongoing Phase 1/1b trial of BP1001-A for advanced solid tumors showing positive early results; and a Phase 1/1b trial of BP1002 for relapsed/refractory AML. The company has developed a molecular biomarker package to identify patients more likely to respond to prexigebersen treatment.
Notable progress includes a patient in the BP1001-A solid tumor trial showing a 15% tumor reduction after nine treatment cycles. The company plans to file an IND application for BP1001-A in obesity treatment for Type 2 Diabetes patients later in 2025.
Bio-Path Holdings (NASDAQ:BPTH) reported positive preclinical study results for BP1001-A as a potential treatment for obesity in Type 2 diabetes patients. The studies demonstrated that BP1001-A enhances insulin sensitivity by downregulating Grb2 protein expression, which helps lower blood glucose levels.
Key findings showed that BP1001-A reduced Grb2 protein expression in myoblast cells and increased phosphorylated AKT and FOXO-1 levels in myoblast and hepatoma cells with insulin present. The company has initiated animal studies and plans to begin a first-in-human Phase 1 clinical trial in 2025 to validate safety, measure pharmacokinetics, and establish dosing for potential pivotal trials.
Stonegate Capital Partners has updated its coverage on Bio-Path Holdings (NASDAQ: BPTH) for the third quarter of 2024. The detailed announcement includes downloadable images, bios, and more information. For the complete announcement, click the image above.
Bio-Path Holdings (NASDAQ:BPTH) has outlined its strategic focus on developing BP1001-A as a potential treatment for obesity in Type 2 diabetes patients. The company's decision is based on scientific evidence suggesting that downregulating growth factor receptor-bound protein 2 (Grb2) could help lower blood glucose levels by affecting insulin signaling.
The company is conducting confirmatory preclinical studies and plans to complete IND-enabling testing in Q4 2024. Simultaneously, Bio-Path announced the discontinuation of its Phase 1 clinical trial of BP1002 for refractory/relapsed lymphoma and chronic lymphocytic leukemia due to enrollment challenges in these niche indications.
Bio-Path Holdings reported Q3 2024 financial results with a net loss of $2.1 million ($0.70 per share), compared to $3.2 million loss in Q3 2023. The company initiated a new obesity program using its DNAbilize® technology, marking its first non-oncology application. Research and development expenses decreased to $1.3 million from $2.3 million year-over-year. The company completed enrollment for the third dosing cohort of BP1002 in venetoclax-resistant AML patients ahead of schedule. In October, Bio-Path closed a $4.0 million private placement. Cash position stood at $0.6 million as of September 30, 2024.
Bio-Path Holdings (NASDAQ: BPTH) announced it will host a conference call and audio webcast on November 15, 2024, at 8:30 a.m. ET to discuss third quarter 2024 financial results and provide a business overview. The company develops DNAbilize®, an RNAi nanoparticle drug technology administered through intravenous transfusion. Their pipeline includes prexigebersen (BP1001) in Phase 2 for blood cancers, BP1001-A in Phase 1/1b for solid tumors, and BP1002 targeting Bcl-2 protein for blood cancers and solid tumors. They're also preparing an IND filing for BP1003, a STAT3 inhibitor.
Bio-Path Holdings (NASDAQ:BPTH) has closed a $4.0 million private placement priced at-the-market under Nasdaq rules. The offering included the issuance of 4,597,702 shares of common stock (or equivalents), series A warrants for up to 6,407,657 shares, and short-term series B warrants for up to 6,407,657 shares at $0.87 per share. Both warrant types have an exercise price of $1.00 per share.
The company plans to use the net proceeds for working capital and general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent. Additionally, certain outstanding warrants from June 2024 were cancelled upon closing of this placement.
Bio-Path Holdings (NASDAQ:BPTH) has announced a $4.0 million private placement priced at-the-market under Nasdaq rules. The company will issue and sell 4,597,702 shares of common stock (or equivalents), along with series A and B warrants to purchase additional shares. The purchase price is set at $0.87 per share, with warrants exercisable at $1.00 per share. The offering is expected to close around October 10, 2024.
H.C. Wainwright & Co. is acting as the exclusive placement agent. Bio-Path intends to use the net proceeds for working capital and general corporate purposes. The securities are being offered under Section 4(a)(2) of the Securities Act and have not been registered. The company has agreed to file a resale registration statement for these securities.
Bio-Path Holdings (NASDAQ:BPTH) has announced two significant developments:
1. Initiation of a therapeutic program to develop BP1001-A for treating obesity and related metabolic diseases, marking the first non-cancer application of their DNAbilize® technology.
2. Completion of enrollment in the third dosing cohort of the ongoing Phase 1/1b clinical trial evaluating BP1002 for refractory/relapsed acute myeloid leukemia (AML) patients, including venetoclax-resistant patients.
The company expects to begin preclinical studies for BP1001-A in Q4 2024, targeting insulin resistance. The rapid enrollment in the BP1002 trial highlights the urgent need for new treatment options in AML.
Bio-Path Holdings (NASDAQ:BPTH) announced a publication in Biomedicines highlighting the therapeutic potential of BP1003 in various cancer types. The article, titled 'BP1003 Decreases STAT3 Expression and Its Pro-Tumorigenic Functions in Solid Tumors and the Tumor Microenvironment,' describes the broad anti-tumor effect of BP1003 in preclinical solid tumor models including breast, ovarian, and pancreatic cancer.
BP1003 is a neutral liposome incorporated with a nuclease resistant P-ethoxy antisense oligodeoxynucleotide targeting the STAT3 mRNA. The company believes BP1003 has the potential to enhance the efficacy of current standard of care chemotherapies in a broad range of difficult to treat cancers. This publication marks Bio-Path's twenty-second peer-reviewed article supporting its DNAbilize® technology.